继发于左心室收缩功能障碍的肺动脉高压：当代诊断与管理
Pulmonary hypertension secondary to left ventricular systolic dysfunction: contemporary diagnosis and management.
作者信息
Shah Ravi V, Semigran Marc J
机构信息
Department of Medicine, Massachusetts General Hospital, Grey Bigelow 8, 55 Fruit Street, Boston, MA 02114, USA.
出版信息
Curr Heart Fail Rep. 2008 Dec;5(4):226-32. doi: 10.1007/s11897-008-0034-9.
Abstract
Pulmonary hypertension secondary to left ventricular systolic dysfunction is often a poor prognostic marker in chronic heart failure. In this article, we review evidence supporting modern strategies addressing pulmonary hypertension in patients with left ventricular systolic dysfunction, including right-sided heart catheterization with vasoreactivity testing and subsequent parenteral, oral, and inhaled therapy. We delineate a diagnostic approach to secondary pulmonary hypertension and outline evidence-based therapeutic strategies for management in acute and chronic heart failure.
摘要
继发于左心室收缩功能障碍的肺动脉高压通常是慢性心力衰竭预后不良的标志。在本文中，我们回顾了支持针对左心室收缩功能障碍患者肺动脉高压的现代治疗策略的证据，包括进行血管反应性测试的右心导管检查以及随后的肠外、口服和吸入治疗。我们阐述了继发性肺动脉高压的诊断方法，并概述了急性和慢性心力衰竭管理的循证治疗策略。
相似文献
1
Pulmonary hypertension secondary to left ventricular systolic dysfunction: contemporary diagnosis and management.
Curr Heart Fail Rep. 2008 Dec;5(4):226-32. doi: 10.1007/s11897-008-0034-9.
2
Pulmonary Hypertension in Advanced Heart Failure: Assessment and Management of the Failing RV and LV.
Curr Heart Fail Rep. 2019 Oct;16(5):119-129. doi: 10.1007/s11897-019-00431-4.
3
Management of pulmonary hypertension in left heart disease.
Ther Adv Cardiovasc Dis. 2013 Jun;7(3):131-51. doi: 10.1177/1753944713477518. Epub 2013 Apr 16.
4
[Pulmonary hypertension in left heart disease: how to define it and how to manage it in 2013?].
Rev Med Suisse. 2013 May 29;9(388):1160-4, 1166-7.
5
Cardiac correlates of exercise induced pulmonary hypertension in patients with chronic heart failure due to left ventricular systolic dysfunction.
Echocardiography. 2008 Apr;25(4):386-93. doi: 10.1111/j.1540-8175.2007.00616.x. Epub 2008 Jan 3.
6
Pulmonary hypertension and right ventricular failure in left ventricular systolic dysfunction.
Curr Opin Cardiol. 2012 May;27(3):262-72. doi: 10.1097/HCO.0b013e3283522098.
7
Pulmonary hypertension and right ventricular dysfunction in left heart disease (group 2 pulmonary hypertension).
Prog Cardiovasc Dis. 2012 Sep-Oct;55(2):104-18. doi: 10.1016/j.pcad.2012.07.007.
8
Pulmonary Hypertension secondary to Left Heart Disease.
Curr Vasc Pharmacol. 2018;16(6):555-560. doi: 10.2174/1570161115666170913105424.
9
10
Determinants of pulmonary hypertension in left ventricular dysfunction.
J Am Coll Cardiol. 1997 Jan;29(1):153-9. doi: 10.1016/s0735-1097(96)00436-6.
引用本文的文献
1
Persistence of pulmonary arterial hypertension after relief of left sided obstructive lesions in small infants: our experience.
Images Paediatr Cardiol. 2017 Jan-Mar;19(1):1-7.
2
Under pressure: pulmonary hypertension associated with left heart disease.
Eur Respir Rev. 2015 Dec;24(138):665-73. doi: 10.1183/16000617.0059-2015.
3
TNM-like classification: a new proposed method for heart failure staging.
ScientificWorldJournal. 2013 Nov 24;2013:175925. doi: 10.1155/2013/175925.
4
Who has advanced heart failure?: definition and epidemiology.
Congest Heart Fail. 2011 Jul-Aug;17(4):160-8. doi: 10.1111/j.1751-7133.2011.00246.x. Epub 2011 Jul 21.
5
Pulmonary hypertension related to left-sided cardiac pathology.
Pulm Med. 2011;2011:381787. doi: 10.1155/2011/381787. Epub 2011 May 29.
本文引用的文献
1
Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial.
Circ Heart Fail. 2008 May;1(1):9-16. doi: 10.1161/CIRCHEARTFAILURE.108.767483.
2
Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.
J Card Fail. 2008 Apr;14(3):189-97. doi: 10.1016/j.cardfail.2007.11.006.
3
Long-term use of sildenafil in the therapeutic management of heart failure.
J Am Coll Cardiol. 2007 Nov 27;50(22):2136-44. doi: 10.1016/j.jacc.2007.07.078. Epub 2007 Nov 13.
4
Effectiveness and safety of treatment with sildenafil for secondary pulmonary hypertension in heart transplant candidates.
Transplant Proc. 2007 Nov;39(9):2856-8. doi: 10.1016/j.transproceed.2007.08.069.
5
Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
Circulation. 2007 Oct 2;116(14):1555-62. doi: 10.1161/CIRCULATIONAHA.107.716373. Epub 2007 Sep 4.
6
Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices.
Ann Thorac Surg. 2007 Jan;83(1):68-71; discussion 71. doi: 10.1016/j.athoracsur.2006.08.051.
7
Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.
Circulation. 2007 Jan 2;115(1):59-66. doi: 10.1161/CIRCULATIONAHA.106.626226. Epub 2006 Dec 18.
8
Nesiritide acutely increases pulmonary and systemic levels of nitric oxide in patients with pulmonary hypertension.
J Card Fail. 2006 Sep;12(7):507-13. doi: 10.1016/j.cardfail.2006.05.004.
9
Combined administration of intravenous dipyridamole and inhaled nitric oxide to assess reversibility of pulmonary arterial hypertension in potential cardiac transplant recipients.
J Heart Lung Transplant. 2005 Nov;24(11):1950-6. doi: 10.1016/j.healun.2005.04.007. Epub 2005 Aug 31.
10
Sildenafil citrate therapy for pulmonary arterial hypertension.
N Engl J Med. 2005 Nov 17;353(20):2148-57. doi: 10.1056/NEJMoa050010.
Zotero 插件